State Street
BDTX icon

State Street’s Black Diamond Therapeutics BDTX Stock Holding History

State Street’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$971K Buy
525,013
+311,500
+146% +$762K ﹤0.01% 3469
2026
Q1 		$455K Hold
213,513
– – ﹤0.01% 3681
2025
Q4 		$519K Hold
213,513
– – ﹤0.01% 3665
2025
Q3 		$809K Hold
213,513
– – ﹤0.01% 3558
2025
Q2 		$530K Sell
213,513
-653,678
-75% -$1.26M ﹤0.01% 3607
2025
Q1 		$1.34M Sell
867,191
-16,250
-2% -$34.1K ﹤0.01% 3366
2024
Q4 		$1.89M Buy
883,441
+74,245
+9% +$213K ﹤0.01% 3336
2024
Q3 		$3.52M Buy
809,196
+118,764
+17% +$646K ﹤0.01% 3110
2024
Q2 		$3.22M Buy
690,432
+573,348
+490% +$3.08M ﹤0.01% 3112
2024
Q1 		$594K Buy
117,084
+1,300
+1% +$5.24K ﹤0.01% 3604
2023
Q4 		$325K Buy
115,784
+39,400
+52% +$92.4K ﹤0.01% 3757
2023
Q3 		$219K Hold
76,384
– – ﹤0.01% 3914
2023
Q2 		$386K Hold
76,384
– – ﹤0.01% 3760
2023
Q1 		$144K Hold
76,384
– – ﹤0.01% 4181
2022
Q4 		$137K Hold
76,384
– – ﹤0.01% 4255
2022
Q3 		$129K Hold
76,384
– – ﹤0.01% 4347
2022
Q2 		$188K Sell
76,384
-292,878
-79% -$681K ﹤0.01% 4224
2022
Q1 		$1.02M Buy
369,262
+4,609
+1% +$16.8K ﹤0.01% 3801
2021
Q4 		$1.94M Buy
364,653
+8,950
+3% +$62.5K ﹤0.01% 3643
2021
Q3 		$3.01M Buy
355,703
+21,352
+6% +$211K ﹤0.01% 3493
2021
Q2 		$4.08M Sell
334,351
-1,460,287
-81% -$28.9M ﹤0.01% 3342
2021
Q1 		$43.5M Buy
1,794,638
+972,021
+118% +$26.2M ﹤0.01% 1841
2020
Q4 		$26.4M Buy
822,617
+543,698
+195% +$17.9M ﹤0.01% 2070
2020
Q3 		$8.43M Buy
278,919
+48,801
+21% +$1.49M ﹤0.01% 2527
2020
Q2 		$9.7M Buy
230,118
+41,095
+22% +$1.51M ﹤0.01% 2438
2020
Q1 		$4.72M Buy
+189,023
New +$5.75M ﹤0.01% 2657

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

State Street's BDTX Position: Q2 2026 in Review

State Street increased its Black Diamond Therapeutics (BDTX) stake by 146% in Q2 2026, buying an estimated $762K and bringing the position to 525,013 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

State Street first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $43.5M in Q1 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • State Street held 525,013 shares of Black Diamond Therapeutics worth $971K as of Q2 2026.
  • State Street bought 311,500 Black Diamond Therapeutics shares in Q2 2026, an estimated $762K.
  • Black Diamond Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3469 holding.
  • State Street first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • State Street's Black Diamond Therapeutics position peaked at $43.5M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.